irinotecan has been researched along with Sarcoma in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 4 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| B, H; Canute Fernandes, S; Rastogi, S | 1 |
| Bisogno, G; Bogart, E; Calareso, G; Casanova, M; Chisholm, JC; Defachelles, AS; Gatz, SA; Le Deley, MC; McHugh, K; Melcon, SG; Merks, JHM; Minard-Colin, V; Probst, A; Rocourt, N; van Rijn, RR | 1 |
| Burrow, TA; Eslinger, C; Koneru, B; Macha, SJ; McCoy, K; Nance, J; Rahman, RL; Reynolds, CP; Ronaghan, CA; Savitski, D; Zhu, C | 1 |
| Balaguer-Lluna, L; Baulenas-Farres, M; Burgueño, V; Carcaboso, AM; Carrasco, R; Castañeda, A; Castillo-Ecija, H; Celis, V; Cruz, O; Cuadrado-Vilanova, M; Garraus, M; Gorostegui, M; Jimenez-Cabaco, A; Krauel, L; Lavarino, C; Manzanares, A; Monterrubio, C; Mora, J; Morales La Madrid, A; Muñoz-Aznar, O; Olaciregui, NG; Pascual-Pasto, G; Perez-Jaume, S; Resa-Pares, C; Salvador, N; Santa-Maria, V; Suñol, M; Torner, F; Vancells, M; Vicario, FJ; Vila-Ubach, M | 1 |
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Ambati, SR; Chaudhry, A; Lopes, EC; Moore, MA; Pera, B; Saxena, A; Shieh, JH; Su, TL; Wong, EW | 1 |
| Attinà, G; Coccia, P; Riccardi, R; Ruggiero, A; Scalzone, M | 1 |
| Choijamts, B; Emoto, M; Kawarabayashi, T; Miyamoto, S; Naganuma, Y; Nakajima, K; Tachibana, K | 1 |
| Patel, SR | 1 |
| Arcamone, G; Bertolini, P; Bisogno, G; Carli, M; Paolucci, P; Prete, A; Provenzi, M; Riccardi, R; Ruggiero, A; Surico, G | 1 |
| Gupta, AA; Pappo, AS | 1 |
| Boven, E; Erkelens, CA; Jansen, WJ; Kolfschoten, GM; Pinedo, HM; Van Ark-Otte, J | 1 |
2 review(s) available for irinotecan and Sarcoma
| Article | Year |
|---|---|
Developing therapeutic pharmaceuticals for the treatment of soft-tissue sarcomas.
Topics: Antineoplastic Agents; Benzamides; Camptothecin; Dacarbazine; Deoxycytidine; Dioxoles; Gemcitabine; Humans; Imatinib Mesylate; Irinotecan; Isoquinolines; Piperazines; Pyrimidines; Sarcoma; Temozolomide; Tetrahydroisoquinolines; Trabectedin | 2002 |
New drugs for the treatment of metastatic or refractory soft tissue sarcomas in children.
Topics: Animals; Camptothecin; Child; Disease Models, Animal; Drug Design; Enzyme Inhibitors; Humans; Irinotecan; Rhabdomyosarcoma; Sarcoma; Survival Rate; Topoisomerase I Inhibitors; Topotecan | 2006 |
2 trial(s) available for irinotecan and Sarcoma
| Article | Year |
|---|---|
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Disease Progression; Drug Administration Schedule; Female; Humans; Infant; Infusions, Intravenous; Irinotecan; Male; Neutropenia; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome | 2006 |
8 other study(ies) available for irinotecan and Sarcoma
| Article | Year |
|---|---|
VIT-0910: Need for Cautious Optimism?
Topics: Adult; Child; Humans; Irinotecan; Rhabdomyosarcoma; Sarcoma; Temozolomide; Therapies, Investigational; Vincristine | 2022 |
Reply to H. B et al.
Topics: Child; Humans; Irinotecan; Rhabdomyosarcoma; Sarcoma; Temozolomide; Therapies, Investigational; Vincristine | 2022 |
Alternative Lengthening of Telomeres in Cancer Confers a Vulnerability to Reactivation of p53 Function.
Topics: Animals; Carcinoma; Humans; Irinotecan; Mice; Neuroblastoma; Sarcoma; Telomerase; Telomere; Telomere Homeostasis; Tumor Suppressor Protein p53 | 2022 |
Prognostic value of patient-derived xenograft engraftment in pediatric sarcomas.
Topics: Adolescent; Animals; Child; Child, Preschool; Disease Models, Animal; Female; Heterografts; Humans; Irinotecan; Male; Mice; Osteosarcoma; Prognosis; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Treatment Outcome; Xenograft Model Antitumor Assays | 2021 |
BO-1055, a novel DNA cross-linking agent with remarkable low myelotoxicity shows potent activity in sarcoma models.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; DNA Damage; Drug Synergism; HCT116 Cells; Humans; Irinotecan; MCF-7 Cells; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Nitrogen Mustard Compounds; Phenylurea Compounds; Sarcoma; Xenograft Model Antitumor Assays | 2016 |
Treatment of childhood sarcoma with irinotecan: bilirubin level as a predictor of gastrointestinal toxicity.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Child; Child, Preschool; Diarrhea; Female; Gastric Mucosa; Humans; Infant; Intestinal Mucosa; Irinotecan; Male; Predictive Value of Tests; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms | 2009 |
Metronomic irinotecan chemotherapy combined with ultrasound irradiation for a human uterine sarcoma xenograft.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Separation; Combined Modality Therapy; Drug Administration Schedule; Female; Flow Cytometry; Humans; Irinotecan; Mice; Mice, Nude; Neovascularization, Pathologic; Sarcoma; Ultrasonic Therapy; Uterine Neoplasms; Xenograft Model Antitumor Assays | 2011 |
Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; RNA, Messenger; Sarcoma; Sarcoma, Experimental; Tumor Cells, Cultured | 1997 |